Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 11 clinical trials
None
Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage

The purpose of this study is to To confirm the predictive value of CCND1 for TPF induction in cN2 patients with OSCC

platelet count
renal function
ccnd1
squamous cell carcinoma
external radiation
  • 19 views
  • 04 Oct, 2021
  • 1 location
None
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6

This research study is studying a targeted therapy as a possible treatment for cancer abnormality in one of the following genes: CCND1, CCND2, CCND3, CDK4, or CDK6. The drug involved in

solid tumour
liver metastasis
solid neoplasm
targeted therapy
neutrophil count
  • 16 views
  • 13 Jun, 2021
  • 1 location
None
Evaluation of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A and/or an Amplification of CCND1 and/or of CDK6

status CDKN2A, CCND1 and CDK6. Following this centralized molecular screening, only patients with HPV negative status and with tumor harboring CDKN2A homozygous deletion and/or CCND1 amplification and/or

platelet count
serum bilirubin
liver metastasis
renal function
head and neck cancer
  • 51 views
  • 25 Jun, 2021
  • 5 locations
None
Bendamustine Obinutuzumab and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

This phase II trial studies how well bendamustine, obinutuzumab, and venetoclax work in treating patients with mantle cell lymphoma. Drugs used in chemotherapy, such as bendamustine and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or …

platelet count
cyclin d1
neutrophil count
obinutuzumab
tumor cells
  • 4 views
  • 16 May, 2021
  • 3 locations
None
CDK4/6 Tumor Abemaciclib Paclitaxel

cancer cell proliferation. Cyclin D1 acts with CDK4 and CDK6 to phosphorylate Rb and promote cell-cycle progression, and CDK4/6 inhibitor might be effective for the patients with CCND1/2/3

  • 0 views
  • 01 May, 2021
  • 1 location
None
Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

This phase II trials studies how well acalabrutinib with or without obinutuzumab works in treating patients with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as obinutuzumab, …

lymphoma
platelet count
lymphoid leukemia
monoclonal protein
direct bilirubin
  • 7 views
  • 04 Sep, 2021
  • 5 locations
None
Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

This phase II trial studies how well venetoclax and acalabrutinib work in treating patients with mantle cell lymphoma that did not respond to previous treatment or has come back. Venetoclax may cause cancer cell death by blocking the mechanism that cancer cells use to stay alive. Acalabrutinib may stop the …

platelet count
neutrophil count
measurable disease
gilbert's syndrome
venetoclax
  • 0 views
  • 04 Mar, 2021
  • 1 location
None
Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer With DNA-Repair Genetic Changes

This phase II trial studies how well olaparib works in treating patients with urothelial cancer with deoxyribonucleic acid (DNA)-repair defects that has spread to other places in the body (advanced or metastatic) and usually cannot be cured or controlled with treatment. PARPs are proteins that help repair DNA mutations. PARP …

atezolizumab
pembrolizumab
nivolumab
neutrophil count
measurable disease
  • 92 views
  • 07 Nov, 2021
  • 4 locations
None
Immune Modulation by Abemaciclib in HNSCC. (AIM Trial)

This is a randomized, parallel, open label Phase II single-arm window trial to assess the clinical and biological effects of neoadjuvant abemaciclib in patients with HPV-negative head and neck squamous cell carcinoma (HNSCC).

  • 0 views
  • 20 Sep, 2021
  • 1 location
None
Vismodegib FAK Inhibitor GSK2256098 Capivasertib and Abemaciclib in Treating Patients With Progressive Meningiomas

This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes …

tumor cells
gsk2256098
vismodegib
  • 0 views
  • 19 Oct, 2021
  • 527 locations